Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome.
Identifieur interne : 002A32 ( PubMed/Checkpoint ); précédent : 002A31; suivant : 002A33Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome.
Auteurs : Davide Corti [Suisse] ; Nadia Passini [Suisse] ; Antonio Lanzavecchia [Suisse] ; Maria Zambon [Royaume-Uni]Source :
- Journal of infection and public health [ 1876-035X ]
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (isolement et purification), Anticorps antiviraux (pharmacologie), Anticorps monoclonaux (isolement et purification), Anticorps monoclonaux (pharmacologie), Biotechnologie (), Cellules CHO, Cricetulus, Facteurs immunologiques (isolement et purification), Facteurs immunologiques (pharmacologie), Facteurs temps, Humains, Immunothérapie (), Infections à coronavirus (), Technologie pharmaceutique ().
- MESH :
- isolement et purification : Anticorps antiviraux, Anticorps monoclonaux, Facteurs immunologiques.
- pharmacologie : Anticorps antiviraux, Anticorps monoclonaux, Facteurs immunologiques.
- Animaux, Biotechnologie, Cellules CHO, Cricetulus, Facteurs temps, Humains, Immunothérapie, Infections à coronavirus, Technologie pharmaceutique.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (isolation & purification), Antibodies, Monoclonal (pharmacology), Antibodies, Viral (isolation & purification), Antibodies, Viral (pharmacology), Biotechnology (methods), CHO Cells, Coronavirus Infections (prevention & control), Coronavirus Infections (therapy), Cricetulus, Humans, Immunologic Factors (isolation & purification), Immunologic Factors (pharmacology), Immunotherapy (methods), Technology, Pharmaceutical (methods), Time Factors.
- MESH :
- chemical , isolation & purification : Antibodies, Monoclonal, Antibodies, Viral, Immunologic Factors.
- chemical , pharmacology : Antibodies, Monoclonal, Antibodies, Viral, Immunologic Factors.
- methods : Biotechnology, Immunotherapy, Technology, Pharmaceutical.
- prevention & control : Coronavirus Infections.
- therapy : Coronavirus Infections.
- Animals, CHO Cells, Cricetulus, Humans, Time Factors.
Abstract
The last century has witnessed the emergence of several previously unknown viruses as life-threatening human pathogens. Several examples include HIV, Ebola, Lujo, and, most recently, the Middle East respiratory syndrome (MERS) and Ebola. In this study, we describe a method for the swift generation of a human-derived monoclonal antibody, known as LCA60, as a treatment for MERS infections. LCA60 antibody was generated using the Cellclone Technology from the immortalized B cells of a human donor recovering from MERS. Only four months were required from the initial screening of B cells to the development of a stable CHO cell line suitable for the production of clinical grade antibody, thereby delineating a rapid pathway for the development of antiviral therapies against emerging viruses. Currently, the LCA60 antibody is being considered for clinical development, which includes prophylaxis in individuals at risk and a treatment for severe MERS-CoV infections.
DOI: 10.1016/j.jiph.2016.04.003
PubMed: 27102927
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:27102927Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome.</title><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, 6500 Bellinzona, Switzerland. Electronic address: davide.corti@humabs.ch.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, 6500 Bellinzona</wicri:regionArea><wicri:noRegion>6500 Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Passini, Nadia" sort="Passini, Nadia" uniqKey="Passini N" first="Nadia" last="Passini">Nadia Passini</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, 6500 Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, 6500 Bellinzona</wicri:regionArea><wicri:noRegion>6500 Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><affiliation wicri:level="1"><nlm:affiliation>Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland; Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland; Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich</wicri:regionArea><wicri:noRegion>8093 Zurich</wicri:noRegion></affiliation></author><author><name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Services Colindale, Public Health England, London NW9 5HT, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Microbiology Services Colindale, Public Health England, London NW9 5HT</wicri:regionArea><wicri:noRegion>London NW9 5HT</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2016 May-Jun</MedlineDate></PubDate></date><idno type="RBID">pubmed:27102927</idno><idno type="pmid">27102927</idno><idno type="doi">10.1016/j.jiph.2016.04.003</idno><idno type="wicri:Area/PubMed/Corpus">001155</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001155</idno><idno type="wicri:Area/PubMed/Curation">001155</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001155</idno><idno type="wicri:Area/PubMed/Checkpoint">002A32</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A32</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome.</title><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, 6500 Bellinzona, Switzerland. Electronic address: davide.corti@humabs.ch.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, 6500 Bellinzona</wicri:regionArea><wicri:noRegion>6500 Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Passini, Nadia" sort="Passini, Nadia" uniqKey="Passini N" first="Nadia" last="Passini">Nadia Passini</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, 6500 Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, 6500 Bellinzona</wicri:regionArea><wicri:noRegion>6500 Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><affiliation wicri:level="1"><nlm:affiliation>Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland; Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland; Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich</wicri:regionArea><wicri:noRegion>8093 Zurich</wicri:noRegion></affiliation></author><author><name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Services Colindale, Public Health England, London NW9 5HT, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Microbiology Services Colindale, Public Health England, London NW9 5HT</wicri:regionArea><wicri:noRegion>London NW9 5HT</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of infection and public health</title><idno type="eISSN">1876-035X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (isolation & purification)</term><term>Antibodies, Monoclonal (pharmacology)</term><term>Antibodies, Viral (isolation & purification)</term><term>Antibodies, Viral (pharmacology)</term><term>Biotechnology (methods)</term><term>CHO Cells</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (therapy)</term><term>Cricetulus</term><term>Humans</term><term>Immunologic Factors (isolation & purification)</term><term>Immunologic Factors (pharmacology)</term><term>Immunotherapy (methods)</term><term>Technology, Pharmaceutical (methods)</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (isolement et purification)</term><term>Anticorps antiviraux (pharmacologie)</term><term>Anticorps monoclonaux (isolement et purification)</term><term>Anticorps monoclonaux (pharmacologie)</term><term>Biotechnologie ()</term><term>Cellules CHO</term><term>Cricetulus</term><term>Facteurs immunologiques (isolement et purification)</term><term>Facteurs immunologiques (pharmacologie)</term><term>Facteurs temps</term><term>Humains</term><term>Immunothérapie ()</term><term>Infections à coronavirus ()</term><term>Technologie pharmaceutique ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Facteurs immunologiques</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Biotechnology</term><term>Immunotherapy</term><term>Technology, Pharmaceutical</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Facteurs immunologiques</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>CHO Cells</term><term>Cricetulus</term><term>Humans</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Biotechnologie</term><term>Cellules CHO</term><term>Cricetulus</term><term>Facteurs temps</term><term>Humains</term><term>Immunothérapie</term><term>Infections à coronavirus</term><term>Technologie pharmaceutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The last century has witnessed the emergence of several previously unknown viruses as life-threatening human pathogens. Several examples include HIV, Ebola, Lujo, and, most recently, the Middle East respiratory syndrome (MERS) and Ebola. In this study, we describe a method for the swift generation of a human-derived monoclonal antibody, known as LCA60, as a treatment for MERS infections. LCA60 antibody was generated using the Cellclone Technology from the immortalized B cells of a human donor recovering from MERS. Only four months were required from the initial screening of B cells to the development of a stable CHO cell line suitable for the production of clinical grade antibody, thereby delineating a rapid pathway for the development of antiviral therapies against emerging viruses. Currently, the LCA60 antibody is being considered for clinical development, which includes prophylaxis in individuals at risk and a treatment for severe MERS-CoV infections. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27102927</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-035X</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><MedlineDate>2016 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Journal of infection and public health</Title><ISOAbbreviation>J Infect Public Health</ISOAbbreviation></Journal><ArticleTitle>Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome.</ArticleTitle><Pagination><MedlinePgn>231-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiph.2016.04.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1876-0341(16)30020-X</ELocationID><Abstract><AbstractText>The last century has witnessed the emergence of several previously unknown viruses as life-threatening human pathogens. Several examples include HIV, Ebola, Lujo, and, most recently, the Middle East respiratory syndrome (MERS) and Ebola. In this study, we describe a method for the swift generation of a human-derived monoclonal antibody, known as LCA60, as a treatment for MERS infections. LCA60 antibody was generated using the Cellclone Technology from the immortalized B cells of a human donor recovering from MERS. Only four months were required from the initial screening of B cells to the development of a stable CHO cell line suitable for the production of clinical grade antibody, thereby delineating a rapid pathway for the development of antiviral therapies against emerging viruses. Currently, the LCA60 antibody is being considered for clinical development, which includes prophylaxis in individuals at risk and a treatment for severe MERS-CoV infections. </AbstractText><CopyrightInformation>Copyright © 2016 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corti</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, 6500 Bellinzona, Switzerland. Electronic address: davide.corti@humabs.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passini</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, 6500 Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzavecchia</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland; Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zambon</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microbiology Services Colindale, Public Health England, London NW9 5HT, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect Public Health</MedlineTA><NlmUniqueID>101487384</NlmUniqueID><ISSNLinking>1876-0341</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001709" MajorTopicYN="N">Biotechnology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013678" MajorTopicYN="N">Technology, Pharmaceutical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27102927</ArticleId><ArticleId IdType="pii">S1876-0341(16)30020-X</ArticleId><ArticleId IdType="doi">10.1016/j.jiph.2016.04.003</ArticleId><ArticleId IdType="pmc">PMC7102728</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Feb;14(2):140-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24355866</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26216974</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10082-3</Citation><ArticleIdList><ArticleId IdType="pubmed">26261336</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2012 Oct 04;17(40):20290</Citation><ArticleIdList><ArticleId IdType="pubmed">23078800</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Intern Med. 2014 Mar 18;160(6):389-97</Citation><ArticleIdList><ArticleId IdType="pubmed">24474051</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Microbiol Spectr. 2014 Oct;2(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">26104354</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2015 Sep 10;373(11):993-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26244879</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li><li>Suisse</li></country></list><tree><country name="Suisse"><noRegion><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name></noRegion><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><name sortKey="Passini, Nadia" sort="Passini, Nadia" uniqKey="Passini N" first="Nadia" last="Passini">Nadia Passini</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002A32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:27102927
|texte= Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:27102927" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |